WHO ICTRP trial
A study to test whether BI 685509 alone or in combination with empagliflozin…
JPRN-jRCT2031220376 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2031220376 |
|---|---|
| Public title | A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or non-alcoholic steatohepatitis (NASH) who have high blood pressure in the portal vein (main vessel going to the liver) |
| Scientific title | Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) incompensated cirrhosis |
| Primary sponsor | Kutsunai Mitsuru |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Argentina;Japan;Austria;Japan;Belgium;Japan;Canada;Japan;China;Japan;Denmark;Japan;France;Japan;Germany;Japan;Israel;Japan;Itay;Japan;Republic of… |
| Conditions | Patients with CSPH in compensated cirrhosis due to HBV, HCV, and NASH with or without T2DM |
| Interventions | Treatment group 1, 2, 3: 685509 (maintenance dose) Treatment group 4: BI 685509 (maintenance dose) + Empagliflozin |
| Registration date | Oct 14, 2022 |
| Target size | 5 |
| Secondary IDs | NCT05282121 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: